Skip to main content

Table 2 Selected patient and tumor characteristics

From: alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies

 

Study population

N = 940

 

N (%)

Randomization arm

 

 E-T-CMF

454 (48.3)

 E-CMF

147 (15.6)

 ET-CMF

339 (36.1)

Age

 

 <50

381 (40.5)

 ≥50

559 (59.5)

Menopausal status

 

 Premenopausal

435 (46.3)

 Postmenopausal

505 (53.7)

Type of surgery

 

 MRM

644 (68.5)

 Breast conserving

296 (31.5)

Tumor size (cm)

 

 ≤2

288 (30.6)

 2,1-5

530 (56.4)

 >5

122 (13.0)

Histological type

 

 Ductal

727 (77.3)

 Lobular

97 (10.3)

 Mixed

72 (7.7)

 Other

44 (4.7)

N of positive nodes

 

 0-3

363 (38.6)

 ≥4

577 (61.4)

Histological grade

 

 I-II

470 (50.0)

 III-Undifferentiated

470 (50.0)

Adjuvant HT

 

 No

178 (18.9)

 Yes

739 (78.6)

 Missing data

23 (2.4)

Adjuvant RT

 

 No

198 (21.1)

 Yes

711 (75.6)

Missing data

31 (3.3)

  1. N, number; E, epirubicin; T, paxlitaxel; C, cyclophosphamide; M, methotrexate; F, 5-FU; MRM, modified radical mastectomy; HT, hormonal therapy; RT, radiotherapy.